response to binding of their ligands (Evans, 1988) . There are two isoforms of the human PR, PRA and PRB, which differ only in that the smaller isoform, PRA, lacks the N-terminal 164 amino acids of the larger isoform, PR-B (Horwitz and Alexander, 1983; Jeltsch et al, 1986; Savouret et al, 1990; Kastner et al, 1990) . PRA and PRB are products of a single gene and are translated from an individual messenger RNA species under the control of distinct promoters (Kastner et al, 1990) . The transcription of both isoforms is indirectly induced by oestradiol via ER (Kastner et al, 1990) . Both PRA and PRB function as ligand-activated transcription factors but several in vitro studies have demonstrated different functional characteristics between these two isoforms. For instance, transcriptional activation of the progesterone responsive element-containing promoters by PRB is more marked than that by PRA, although the differences are cell-specific (Kastner et al, 1990; Wen et al, 1994; Giangrande et al, 1997) . In addition, PRA can also act as a transcriptional inhibitor of other steroid hormone receptors, including ER and PRB (Wen et al, 1994; Giangrande et al, 1997; Vegeto et al, 1993; Kraus et al, 1995) . Results of these studies indicate that the relative levels of PRA and PRB within target cells may determine the nature and functional responses to progesterone.
In the normal human endometrium (Mote et al, 1999; Critchley et al, 1998; Mangal et al, 1997; Wang et al, 1998) , leiomyoma (Viville et al, 1997; Fujimoto et al, 1998) and endometrial carcinoma (Kumar et al, 1998; Fujimoto et al, 1995) several studies have examined the relative abundance of PRA and PRB expression, and all studies to date support the presence of distinct pathways of progesterone actions in these tissues. However, the expression of PRA and PRB in epithelial ovarian cancer and their clinical significance have not been examined. Therefore, in this study, we evaluated the expression of PRA and PRB in human epithelial ovarian carcinoma using immunohistochemistry and RT-PCR, and their significance as prognostic indicators in epithelial ovarian cancer. We also evaluated the relationship between PR isoforms and ER-α immunohistochemically, because of the unique in vitro activation-inhibition interactions of these sex steroid receptors described above.
MATERIALS AND METHODS
We studied a total of 107 cases of common epithelial ovarian carcinoma. The clinicopathological features of the patients examined are summarized in Table 1 . Information regarding age, performance status on admission, histology, stage, grade, residual tumour after primary surgery, response to primary chemotherapy, and overall survival was retrieved from the review of patient charts. Median follow-up time of the patients in this study was 54 months (18-112 months). Seventy-seven patients (71.9%) were optimally cytoreduced at the time of surgery. The great majority of patients (83.2%) received platinum-containing chemotherapy, and approximately half of them (49.4%) received chemotherapy consisting of cisplatin, adriamycin and cyclophosphamide (CAP). Moreover, more than half of the patients (62.5%) who had measurable disease after primary surgery responded to chemotherapy. It was difficult to evaluate the response to primary chemotherapy in relation to survival because 75 of the 107 patients (72.0%) were optimally cytoreduced with primary surgery, and thus they could not be evaluated (NE) on their response to chemotherapy. Performance status was defined according to WHO criteria (World Health Organization, 1979) . Histology, stage and grade were determined according to FIGO criteria (International Federation of Gynecology and Obstetrics, 1987; Pettersson, 1994) . Residual disease was determined by the amount of unresectable tumour left following primary cytoreductive surgery. Optimal cytoreduction was defined as no gross residual tumour greater than 2 cm in diameter, whereas suboptimal cytoreduction was defined as any gross residual disease remaining greater than 2 cm in diameter. Response to primary chemotherapy was assessed according to WHO criteria (World Health Organization, 1979) . Overall survival was calculated from the time of initial surgery to death, or the date of last contact. Survival times of patients still alive or lost to follow up were censored in February 2000. All of these archival specimens were retrieved from the surgical pathology files at Tohoku University Hospital, Sendai, and Miyagi Prefectural Cancer Center, Natori, Japan. These specimens were all fixed in 10% formalin and embedded in paraffin. Among these 107 cases, 16 cases were available for examination by reverse transcriptionpolymerase chain reaction (RT-PCR) analysis. These specimens were dissected immediately into small pieces following gross dissection, quickly transferred to liquid nitrogen, and then stored at -80°C until further use. The research protocol was approved by the ethics committee of Tohoku University School of Medicine, Sendai, Japan.
Immunohistochemistry
Immunohistochemical analysis was performed using the streptavidin-biotin amplification method using a Histofine Kit (Nichirei, Tokyo, Japan), and have been previously described in detail (Hirasawa et al, 1997) . The characteristics of the primary antibodies employed in this study are summarized in Table 2 . The hPRa2 and hPRa3 antibodies recognize PRB and PRA and B, respectively. The hPRa7 antibody employed in this study recognizes both PRA and PRB on immunoblot analysis (Clarke et al, Significant difference of LIs was observed for performance status and histology (P < 0.05); Performance status score: 0 = asymptomatic and fully active; 1 = symptomatic, fully ambulatory, restricted in physically strenuous activity; 2 = symptomatic, ambulatory, capable of self-care, more than 50% of waking hours are spent out of bed; 3 = symptomatic, limited self-care, spends more than 50% of time in bed, but not bedridden; 4 = completely disabled, no self-care, bedridden 1987), but specifically recognizes PRA when utilized for immunohistochemistry (Mote et al, 1999) . The ER antibody recognizes ER-α, the traditinal estrogen receptor, but not ER-β. The antigen-antibody complex was visualized with 3,3′-diaminobenzidine (DAB) solution (1 mM DAB, 50 mM Tris-HCl buffer, pH 7.6, and 0.006% H 2 O 2 ), and counterstained with haematoxylin. Proliferative-phase endometrial glands were used as positive controls for PR isoforms and ER-α (Clarke et al, 1987) . As negative controls, 0.01 M phosphate buffered saline and normal mouse IgG were used in place of primary antibodies. No specific immunoreactivity was detected in these tissue sections.
Scoring of immunostaining
For evaluation of PRA, PRB, PRAB and ER-α immunoreactivity, labeling index (LI) was obtained in carcinoma cells as described by Sasano et al (1996) . We obtained LI in the following manner. Two of the authors (JA and TM) independently evaluated at least 500 carcinoma cells microscopically. These fields of evaluation were determined by these two authors prior to evaluation using double-headed light microscopy. The mean value was obtained when interobserver differences were less than 5%. Immunostained slides were simultaneously evaluated using double-headed light microscopy when interobserver differences were greater than 5%. Intraobserver differences were less than 5% in this study.
RT-PCR
Total RNA was extracted by homogenizing tissue specimens in guanidinium thiocyanate followed by ultracentrifugation in caesium chloride, as described previously (Sambrook et al, , and quantified spectrophotometrically at 260 nm. An RT-PCR kit (SUPERSCRIPT Preamplification system, Gibco-BRL, Grand Island NY, USA) was employed in the synthesis and amplification of cDNA. cDNAs were synthesized from 5 µg of total RNA using oligo (dT) primer and reverse transcription was carried out for 50 min at 42°C with SUPERSCRIPT II reverse transcriptase. After an initial 1 min denaturation step at 94°C, 35-cycle PCRs were carried out on a DNA thermal cycler (PTC-200 DNA Engine, MJ Research Inc, USA) under the following conditions: 1 min denaturation at 94°C, 1 min annealing at 56°C, and a 2 min extension at 72°C. Primers for PCR reactions were as follows; PRB (Kumar et al, 1998) : 5′ sense-ACAGAATTCAT-GACTGAGCTGAAGGCAAAGGGT and 3′ antisense-ACAA-GATCTCAAACAGGCACCAAGAGCTGCTGA (744-1173, 429 bp); PRAB (Kumar et al, 1998) 
Statistical analysis
Statistical analysis was performed using Stat View 5.0 (SAS Institute Inc, North Carolina, USA) software. The statistical significance of association between hormone-receptor status and characteristics of the patients was evaluated using a Mann-Whitney U-test, Kruskal-Wallis, and Scheffe analysis. Correlation among scored PR isoforms and ER-α immunohistochemistry was also assessed using a Spearman rank correlation. Univariate analysis of prognostic significance for prognostic factors was performed using a log-rank test, after each survival curve was obtained by the Kaplan-Meier method. Multivariate analysis of survival time was performed with Cox's proportional hazards model. All patients who could be assessed were included in the intention-to-treat analysis. A result was considered significant when the P value was less than 0.05.
RESULTS
Results of immunohistochemistry are summarized in Table 1 . Immunoreactivity for PR isoforms and ER-α were confined exclusively to the nuclei of tumour cells. No immunoreactivity, however, was detected in stromal cells (Figure 1 ). Median LI for PRB was 43.2% (range 0-93.2%), while that of PRA was 2.4% (0-58.4%). In all histological types and age groups, PRB LI was significantly higher than PRA LI (P < 0.01). No significant correlations were detected between PRAB, PRA or PRB LI and any of the clinicopathological parameters in the patients examined in this study. There was a highly significant correlation between ER-α and PRB LI (r s = 0.60, P < 0.0001), and a weak correlation was also detected between ER-α and PRA LI (r s = 0.28, P = 0.038, Figure 2) .
Results of univariate analysis of prognostic significance for each variable, with respect to survival, are summarized in Table 3 . In this analysis, we determined the positive cases as those with an LI of more than 10%. There were 35.5% and 71.9% PRA-and PRB-positive cases, respectively. Among the clinicopathological factors examined, those significantly associated with overall survival were histology, stage, performance status, residual tumour, PRAB, PRB, and ER-α immunoreactivity. In multivariate Heat in an autoclave for 5 min in citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0)
analysis, PRB immunoreactivity was a significant (P = 0.037) predictor of overall survival but not PRAB or ER-α (Table 4 , Figure 3 ). Performance status, stage, and residual tumour all turned out to be independent prognostic factors. Results of RT-PCR analysis for each histologic subtype are summarized in Figure 4 . The expression of the mRNAs for PRAB and PRB are: serous, 4/5 and 3/5; mucinous, 3/3 and 3/3; endometrioid, 2/3 and 
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DISCUSSION
Human epithelial ovarian carcinoma is believed to be a sex steroid hormone-dependent neoplasm, but the biological significance of PR, especially its role in growth regulation, and its correlation to clinical outcome in patients, has remained in dispute. Several groups of investigators reported no significant difference in the survival of ovarian cancer patients with respect to PR levels (Bizzi et al, 1988; Geisler et al, 1996; Masood et al, 1989) , while some other studies have reported that a higher PR status correlated well with increased survival (Inversen et al, 1986; Masood et al, 1989; Slotman et al, 1989; Kommoss et al, 1992; Hempling et al, 1998; Langdon et al, 1998) . Review of these reports indicates that the difference in these studies may be due to the heterologous composition of the patient population. For example, several groups of investigators included tumours of low malignant potential and others included only cases with advanced stage of cancer (Masood et al, 1989; Geisler et al, 1996; Hempling et al, 1998) . Hempling et al (1998) and Inversen et al (1986) both demonstrated PR as a significant prognostic factor following multivariate analysis, but both examined only advanced (stage III-IV) epithelial ovarian carcinoma. Therefore, in this study we evaluated only epithelial ovarian carcinoma without low malignant potential, in all stages and all major histologic subtypes using a multivariate analysis. The identification of PR subtypes demonstrates that the analysis of subtypes for PR can provide new insights into the biological roles of PR in human epithelial ovarian carcinoma. In our study, PRB is dominantly expressed in all types or groups of epithelial ovarian carcinoma using both immunohistochemistry and RT-PCR. In addition, PRB, but not PRAB, immunoreactivity turned out to be an independent prognostic factor following multivariate analysis. In all previous studies on PR in ovarian epithelial carcinoma, PR isoforms were not evaluated separately as in PRAB in our present study. Therefore, the discrepancy between the results of previous studies and our present examination may be due to the evaluation of PR subtype in our study, and the analysis of PR isoforms considered important in the evaluation of the survival of patients diagnosed with epithelial ovarian carcinoma. Fujimoto et al (1995) reported the expression of PR isoform mRNAs in ovarian carcinoma using RT-PCR. In their study, six out of ten cases expressed only PRB mRNA. They subsequently concluded that the dominancy of PRB mRNA expression was associated with the advanced clinical stage of ovarian cancer (Fujimoto et al, 1995) . Results of their study, especially the dominance of PRB, but not PRA mRNA, were consistent with those of our present study (Fujimoto et al, 1995) . Therefore, the dominant expression of PRB is considered to be a characteristic feature of ovarian cancer, in contrast to breast and endometrial carcinoma, in which PRA is the dominant subtype of PR (Kumar et al, 1998; Graham et al, 1996) .
The biological role of progesterone in epithelial ovarian carcinoma is unknown, but progesterone is, in general, considered to function antagonistically to oestrogen-mediated cell proliferation (Clarke and Sutherland, 1990) . PRA has been reported to be a transcriptional inhibitor of ER (Simpson et al, 1998) , and PRB has the ability to up-regulate the transcription of genes required for cell differentiation (Kumar et al, 1998) . The transcriptional activation of PRB is more marked than PRA (Kastner et al, 1990) , which suggests that the inhibitory effects on cell proliferation by progesterone is, at least, initially mediated through PRB. Friedlander et al (1989) described a significantly lower S-phase fraction among PR-positive tumours compared with PR-negative tumours. Additionally, they demonstrated that a significantly greater proportion of diploid tumors were PR-positive than were aneuploid tumours (Friedlander et al, 1989) . Both tumour ploidy and proliferative activity, determined by S-phase fraction, have been demonstrated to be significant determinants in the survival of patients with epithelial ovarian cancer (Erhardt et al, 1984; Volm et al, 1985) . Therefore, ovarian epithelial carcinoma cases associated with functional PR, especially PRB, and sufficient in situ availability of progesterone are considered to be associated with better clinical outcome. This may be due to the inhibitory actions of progesterone on tumour cell proliferation, but this hypothesis awaits further investigation for clarification. Kumar et al (1998) examined the expression of PRA and PRB in endometrial carcinoma and reported that selective down-regulation of PRB may represent an insufficient response to progestin therapy in patients with poorly differentiated endometrial carcinoma (Kumar et al, 1998) . Similar results were also reported in breast carcinoma, i.e. tumours containing primarily PRA related to poor response to endocrine agents (Geisler et al, 1996) . These studies have demonstrated that the dominant expression of PRB suggests a good response for progestin in breast and endometrial cancer patients, although the clinical usefulness of sex steroid hormones in the treatment of ovarian cancer has yet to be determined (Ahlgren et al, 1993) .
There was, in general, a good correlation between ER-α and PR in epithelial ovarian carcinoma, suggesting that the regulation of PR, especially of PRB, may be under oestrogen control in ovarian epithelial carcinoma, consistent with the results of previous in vitro studies (Kastner et al, 1990; Savouret et al, 1990) . Both PRA and PRB mRNAs have been demonstrated to be increased by oestrogen, but between these two isoforms, preferential up-regulation of PRB by oestrogen has been reported in the T47D human breast carcinoma cell line (Graham et al, 1995) , and in human endometrial tissue (Mangal et al, 1997) . However, it has also been reported that the stimulatory effects of oestrogen on PRA protein levels were greater than PRB in chicken oviduct (Syvala et al, 1997) , suggesting that oestrogen stimulation of PRA and PRB is likely to be cell-, tissue-, and species-specific. In addition, mechanisms other than those under ER control can influence PR expression, as was demonstrated in PR-positive, ER-negative breast tumours (Horwitz, 1981) . PR expression has been demonstrated to be regulated by growth factors (Katzenellenbogen and Norman, 1990) , and ER-α knockout mice continue to express a low level of PR mRNA (Shughrue et al, 1997) . Therefore, further investigations are required to clarify the possible mechanisms of regulation of PRA and PRB in human epithelial ovarian carcinoma.
